Study IDs Clinical Factors Tied to Free Tissue Transfer Reoperation

Share this content:
Study IDs Clinical Factors Tied to Free Tissue Transfer Reoperation
Study IDs Clinical Factors Tied to Free Tissue Transfer Reoperation

FRIDAY, Dec. 1, 2017 (HealthDay News) -- Certain clinical factors, including wound complications, are associated with reoperation and prolonged hospitalization in patients undergoing free tissue transfer (FTT) for reconstruction related to head and neck cancer, according to a study published online Nov. 30 in JAMA Facial Plastic Surgery.

William W. Thomas, M.D., from the University of Pennsylvania, and colleagues retrospectively reviewed data from the American College of Surgeons National Surgical Quality Improvement Program (2012 to 2014). The authors sought to examine patient and surgical variables associated with reoperation and length of stay following surgical procedures (1,115 patients) for malignant neoplasm of the head and neck involving microvascular FTT reconstruction.

The researchers found that prolonged length of stay was predicted by return to the operating room (odds ratio [OR], 4.8), smoking (OR, 2.1), clean-contaminated wound (OR, 2.2), bony flap (OR, 1.8), age (OR, 1.5), and operative time (OR, 1.2). A total of 225 patients underwent reoperation (298 times), with a mean time to reoperation of 8.0 days. The majority of reoperations (80 percent) occurred before discharge from the primary operation. Neck exploration and incision or drainage of neck were the most common reasons for reoperation (12.4 and 11.7 percent, respectively).

"Wound class of index operation, subsequent wound-related complications, and long duration of the index operation were the primary drivers of increased risk for reoperation and, therefore, prolonged hospitalization," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »